Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Genfit S.A. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
GNFT
Nasdaq
2834
www.genfit.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Genfit S.A.
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders
- Feb 10th, 2025 6:30 am
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
- Feb 6th, 2025 9:10 pm
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
- Jan 30th, 2025 7:40 am
GENFIT Announces 2025 Financial Calendar
- Jan 29th, 2025 9:10 pm
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
- Jan 13th, 2025 9:10 pm
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
- Nov 13th, 2024 9:10 pm
GENFIT Reports Third Quarter 2024 Financial Information
- Nov 7th, 2024 9:10 pm
High Growth Tech Stocks in France for October 2024
- Oct 17th, 2024 7:08 am
High Growth Tech Stocks in France to Watch This October 2024
- Oct 15th, 2024 7:08 am
Believe Leads These 3 High Growth Tech Stocks In France
- Oct 14th, 2024 7:06 am
High Growth Tech Stocks In France October 2024
- Oct 11th, 2024 7:05 am
High Growth Tech Stocks in France to Watch October 2024
- Oct 10th, 2024 7:04 am
Exclusive Networks And 2 High Growth Tech Stocks In France
- Oct 9th, 2024 7:06 am
Esker And Two High Growth Tech Stocks In France
- Sep 24th, 2024 7:06 am
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
- Sep 23rd, 2024 5:30 am
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
- Sep 19th, 2024 8:10 pm
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
- Jul 26th, 2024 11:45 am
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
- Jun 17th, 2024 8:10 pm
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
- Jun 10th, 2024 9:22 pm
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
- May 29th, 2024 8:10 pm
Scroll